Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Bibliographic Details
Main Authors: Maitland, Michael L, Levine, Matthew R, Lacouture, Mario E, Wroblewski, Kristen E, Chung, Christine H, Gordon, Ilyssa O, Szeto, Livia, Ratko, Gail, Soltani, Keyoumars, Kozloff, Mark F, Hoffman, Philip C, Salgia, Ravi, Carbone, David P, Karrison, Theodore G, Vokes, Everett E
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893521/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893521/

Similar Items